
argenx NV ADR (ARGX): VYVGART Growth Drives a Buy Case
argenx is scaling rapidly on VYVGART strength, with Q2 2026 product sales up 60% year over year and a deep autoimmune pipeline supporting the next leg of growth. The stock remains a Buy, though valuation is already reflecting much of the execution.





